Page last updated: 2024-11-12

2-amino-6-boronohexanoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID10214423
CHEMBL ID2348500
SCHEMBL ID215522
MeSH IDM0336252

Synonyms (4)

Synonym
2-amino-6-boronohexanoic acid
SCHEMBL215522
CHEMBL2348500
PD027399

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Arginase is an enzyme that limits substrate L-arginine bioavailability for the production of nitric oxide by the nitric oxide synthases and produces L-ornithine, which is a precursor for collagen formation and tissue remodeling."( Arginase inhibition prevents bleomycin-induced pulmonary hypertension, vascular remodeling, and collagen deposition in neonatal rat lungs.
Belik, J; Dhaliwal, R; Grasemann, H; Ivanovska, J; Jankov, RP; Kantores, C; McNamara, PJ; Scott, JA, 2015
)
0.42
" Therefore, we evaluated the ability of the arginase inhibitor, 2 (S)-amino-6-boronohexanoic acid (ABH), to attenuate pneumoperitoneum-induced decrease of NO bioavailability and lung injury."( The effects of arginase inhibitor on lung oxidative stress and inflammation caused by pneumoperitoneum in rats.
Cho, JS; Kim, OS; Na, S; Oh, YJ, 2015
)
0.42
"Pneumoperitoneum decreases NO bioavailability and increases the inflammation cytokines, resulting in organ injuries."( The effects of arginase inhibitor on lung oxidative stress and inflammation caused by pneumoperitoneum in rats.
Cho, JS; Kim, OS; Na, S; Oh, YJ, 2015
)
0.42
"By increasing NO bioavailability and suppressing oxidative stress and inflammation, pretreatment with an arginase inhibitor may protect against lung injury caused by pneumoperitoneum."( The effects of arginase inhibitor on lung oxidative stress and inflammation caused by pneumoperitoneum in rats.
Cho, JS; Kim, OS; Na, S; Oh, YJ, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Arginase-1Homo sapiens (human)IC50 (µMol)1.12500.31101.60546.0000AID741595; AID741598
Arginase-2, mitochondrialHomo sapiens (human)IC50 (µMol)1.92001.92002.03502.1500AID741597
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
urea cycleArginase-1Homo sapiens (human)
adaptive immune responseArginase-1Homo sapiens (human)
arginine catabolic processArginase-1Homo sapiens (human)
negative regulation of T cell proliferationArginase-1Homo sapiens (human)
defense response to protozoanArginase-1Homo sapiens (human)
innate immune responseArginase-1Homo sapiens (human)
negative regulation of activated T cell proliferationArginase-1Homo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayArginase-1Homo sapiens (human)
positive regulation of neutrophil mediated killing of fungusArginase-1Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionArginase-1Homo sapiens (human)
arginine catabolic process to ornithineArginase-1Homo sapiens (human)
urea cycleArginase-2, mitochondrialHomo sapiens (human)
ureteric bud developmentArginase-2, mitochondrialHomo sapiens (human)
adaptive immune responseArginase-2, mitochondrialHomo sapiens (human)
negative regulation of type 2 immune responseArginase-2, mitochondrialHomo sapiens (human)
nitric oxide biosynthetic processArginase-2, mitochondrialHomo sapiens (human)
striated muscle contractionArginase-2, mitochondrialHomo sapiens (human)
regulation of interleukin-1 beta productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of interleukin-13 productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of interleukin-17 productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of tumor necrosis factor productionArginase-2, mitochondrialHomo sapiens (human)
innate immune responseArginase-2, mitochondrialHomo sapiens (human)
negative regulation of macrophage inflammatory protein 1 alpha productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of chemokine (C-C motif) ligand 4 productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of chemokine (C-C motif) ligand 5 productionArginase-2, mitochondrialHomo sapiens (human)
negative regulation of defense response to bacteriumArginase-2, mitochondrialHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processArginase-2, mitochondrialHomo sapiens (human)
negative regulation of activated CD8-positive, alpha-beta T cell apoptotic processArginase-2, mitochondrialHomo sapiens (human)
negative regulation of CD4-positive, alpha-beta T cell proliferationArginase-2, mitochondrialHomo sapiens (human)
positive regulation of cellular senescenceArginase-2, mitochondrialHomo sapiens (human)
arginine catabolic process to ornithineArginase-2, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
protein bindingArginase-1Homo sapiens (human)
arginase activityArginase-1Homo sapiens (human)
manganese ion bindingArginase-1Homo sapiens (human)
arginase activityArginase-2, mitochondrialHomo sapiens (human)
protein bindingArginase-2, mitochondrialHomo sapiens (human)
manganese ion bindingArginase-2, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
extracellular regionArginase-1Homo sapiens (human)
extracellular spaceArginase-1Homo sapiens (human)
nucleusArginase-1Homo sapiens (human)
cytosolArginase-1Homo sapiens (human)
azurophil granule lumenArginase-1Homo sapiens (human)
specific granule lumenArginase-1Homo sapiens (human)
cytosolArginase-1Homo sapiens (human)
cytoplasmArginase-1Homo sapiens (human)
mitochondrial matrixArginase-2, mitochondrialHomo sapiens (human)
cytoplasmArginase-2, mitochondrialHomo sapiens (human)
mitochondrionArginase-2, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID741595Inhibition of human Arg12013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
2-Substituted-2-amino-6-boronohexanoic acids as arginase inhibitors.
AID741597Inhibition of human Arg2 by colorimetric assay2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
2-Substituted-2-amino-6-boronohexanoic acids as arginase inhibitors.
AID741598Inhibition of human recombinant full length Arg1 using L-arginine as substrate assessed as urea level after 1 hr by colorimetric assay2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
2-Substituted-2-amino-6-boronohexanoic acids as arginase inhibitors.
AID741596Selectivity ratio of IC50 for human Arg1 to IC50 for human Arg22013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
2-Substituted-2-amino-6-boronohexanoic acids as arginase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (15.79)18.2507
2000's6 (31.58)29.6817
2010's10 (52.63)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.83 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]